RYJ - Invesco Raymond James SB-1 Equity ETF
Stock Price: $59.41 USD
0.96 (1.64%)
Updated Apr 21, 2021 4:00 PM EDT - Market closed
After-hours: $59.41 +0.00 (0.00%) Apr 21, 8:00 PM
Assets | $135.79M |
NAV | $58.46 |
Expense Ratio | 0.76% |
PE Ratio | 51.39 |
Beta (5Y) | 1.49 |
Dividend (ttm) | $0.14 |
Dividend Yield | 0.24% |
Ex-Dividend Date | Dec 21, 2020 |
1-Year Return | - |
Trading Day | April 21 |
Last Price | $59.41 |
Previous Close | $58.46 |
Change ($) | 0.96 |
Change (%) | 1.64% |
Day's Open | 58.38 |
Day's Range | 58.38 - 59.41 |
Day's Volume | 428 |
52-Week Range | 29.94 - 59.93 |
Fund Description
The investment seeks to track the investment results (before fees and expenses) of the Raymond James SB-1 Equity Index (the underlying index). The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, the index provider compiles, maintains, and calculates the underlying index, which is comprised of U.S.-listed equity securities that are rated Strong Buy 1 (SB-1) by an affiliate of the index provider. The fund is non-diversified.
Asset Class Equity | Sector Mid Cap |
Region North America | Inception Date May 19, 2006 |
Exchange NYSEARCA | Ticker Symbol RYJ |
Index Tracked Raymond James SB-1 Equity Index |
Top 10 Holdings
6.84% of assetsName | Symbol | Weight |
---|---|---|
ORBCOMM, Inc. | ORBC | 0.92% |
Apellis Pharmaceuticals | APLS | 0.68% |
Kansas City Southern | KSU | 0.68% |
Black Stone Minerals | BSM | 0.67% |
UnitedHealth | UNH | 0.66% |
Health Catalyst | HCAT | 0.66% |
PotlatchDeltic | PCH | 0.65% |
Zimmer Biomet | ZBH | 0.65% |
RingCentral | RNG | 0.64% |
AutoZone | AZO | 0.64% |
Dividends
Ex-Dividend | Amount | Pay Date |
---|---|---|
Dec 21, 2020 | $0.143 | Dec 31, 2020 |
Dec 23, 2019 | $0.096 | Dec 31, 2019 |
Dec 24, 2018 | $0.522 | Dec 31, 2018 |
Dec 23, 2016 | $0.595 | Dec 30, 2016 |
Dec 24, 2015 | $0.301 | Dec 31, 2015 |
Dec 24, 2014 | $0.091 | Dec 31, 2014 |
News
There are no news available yet.